Pharma Pioneer

Gynica Initiates Innovative IntraVag© Clinical Trial for Endometriosis Treatment

19 May 2024
3 min read

Gynica, a biotech startup focused on women's health, has initiated a groundbreaking Phase 1 clinical trial in conjunction with Endometriosis Awareness Month, aiming to improve the lives of over 200 million women affected by the condition globally. The study, to be conducted at Careggi University Hospital in Florence, will assess the IntraVag© drug delivery system and two unique, non-hormonal drug candidates, S-301 and S-302, for their safety, tolerability, and pharmacokinetic profile.
Founded in 2019, Gynica is dedicated to addressing endometriosis, a prevalent and debilitating disease that leads to the abnormal growth of tissue similar to the lining of the uterus in places outside the uterus, significantly impacting the quality of life for approximately one in ten women of reproductive age. Despite the condition's significant economic burden, estimated at $180 billion annually by the World Economic Forum and McKinsey's Health Institute, endometriosis remains a largely untreated area with a pressing need for innovative and effective treatments.
The clinical trial will explore Gynica's proprietary cannabinoid-based formulations, which are administered intravaginally, leveraging the therapeutic potential of cannabinoids in women's health. The study is to be headed by Prof. Felice Petraglia, a leading expert in endometriosis and a former president of the Society for Endometriosis and Uterine Disorders (SEUD). The focus will be on how these cannabinoids interact with the endocannabinoid system (ECS), which is prevalent in reproductive organs like the uterus and ovaries, potentially offering relief from endometriosis-related pain and reducing inflammation associated with the disease.
Gynica's IntraVag technology facilitates the targeted and controlled release of active pharmaceutical ingredients (APIs) to the intended organs. The company is working towards obtaining regulatory approval from the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA). With successful results from the Phase 1 trial, Gynica intends to swiftly proceed to Phase 2 efficacy trials.
Yotam Hod, CEO of Gynica, expressed excitement about the trial, highlighting its significance in the company's mission to transform care for endometriosis patients and enhance their quality of life. Prof. Petraglia emphasized the importance of non-hormonal treatments for endometriosis-associated pain, particularly for patients in need of long-term management and for gynecologists seeking new therapeutic options with diverse mechanisms of action.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

Positive Phase 1 Results for IMM-1-104 in RAS-Mutant Tumor Clinical Trial
Pharma Pioneer
3 min read
Positive Phase 1 Results for IMM-1-104 in RAS-Mutant Tumor Clinical Trial
19 May 2024
Immuneering Corporation has reported encouraging results from the Phase 1 segment of its Phase 1/2a clinical trial for IMM-1-104.
Read →
RECCE® 327 Phase I/II Trial Advances with Next Dosage Cohort for UTIs and Urosepsis
Pharma Pioneer
2 min read
RECCE® 327 Phase I/II Trial Advances with Next Dosage Cohort for UTIs and Urosepsis
19 May 2024
Recce Pharmaceuticals Ltd, a company focused on developing synthetic anti-infectives to combat antibiotic resistance and emerging viral threats, has initiated a new phase in its clinical trials.
Read →
Promising Early Results from NXP800 Trial in Treating Platinum-Resistant Ovarian Cancer
Pharma Pioneer
2 min read
Promising Early Results from NXP800 Trial in Treating Platinum-Resistant Ovarian Cancer
19 May 2024
Preliminary results from a Phase 1b clinical trial of the drug NXP800, developed by Nuvectis Pharma, Inc., have shown promising signs in the treatment of platinum-resistant ARID1a-mutated ovarian cancer.
Read →
NUV-1511 Phase 1/2 Trial Begins with First Patient Dosing for Advanced Tumor Treatment
Pharma Pioneer
2 min read
NUV-1511 Phase 1/2 Trial Begins with First Patient Dosing for Advanced Tumor Treatment
19 May 2024
Nuvation Bio has initiated clinical trials for its first drug-drug conjugate (DDC), NUV-1511.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.